Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug that works as a reversible
Bruton's tyrosine kinase (BTK) inhibitor; unlike other BTK inhibitors it also works against some mutated forms of BTK.[1][2][3][4][5]Merck paid $2.7 billion to acquire the company ArQule and the drug, which is being investigated as a cancer treatment.[6]
References
^Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z.H.; Paszkiewicz-Kozik, Ewa (1 June 2023). "BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations". Journal of Clinical Oncology. 41 (16_suppl): TPS7594.
doi:
10.1200/JCO.2023.41.16_suppl.TPS7594.
S2CID259080098.
Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug that works as a reversible
Bruton's tyrosine kinase (BTK) inhibitor; unlike other BTK inhibitors it also works against some mutated forms of BTK.[1][2][3][4][5]Merck paid $2.7 billion to acquire the company ArQule and the drug, which is being investigated as a cancer treatment.[6]
References
^Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z.H.; Paszkiewicz-Kozik, Ewa (1 June 2023). "BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations". Journal of Clinical Oncology. 41 (16_suppl): TPS7594.
doi:
10.1200/JCO.2023.41.16_suppl.TPS7594.
S2CID259080098.